A randomized controlled trial to evaluate the effect of influenza vaccination and probiotic supplementation on immune response and incidence of influenza-like illness in an elderly population in Indonesia

To investigate the effect of influenza vaccination with or without probiotic supplementation on the immune response and incidence of influenza-like illness (ILI) in the elderly. A randomized double-blind, placebo-controlled trial with a modified factorial design was conducted in 554 healthy elderly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2021-12, Vol.16 (12), p.e0250234-e0250234
Hauptverfasser: Koesnoe, Sukamto, Masjkuri, Nuning, Adisasmita, Asri, Djauzi, Samsuridjal, Kartasasmita, Cissy, Sundoro, Julitasari, Nadjib, Mardiati, Korib, Mondastri, Muthia, Alisa Nurul, Muzellina, Virly Nanda, Habibah, Ummu, Nursyirwan, Saskia Aziza, Djaya, Kristoforus Hendra, Bachtiar, Novilia Sjafri, Sari, Rini Mulia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To investigate the effect of influenza vaccination with or without probiotic supplementation on the immune response and incidence of influenza-like illness (ILI) in the elderly. A randomized double-blind, placebo-controlled trial with a modified factorial design was conducted in 554 healthy elderly subjects aged 67 ± 5.6 (ranging from 60-90) years old in the Primary Health Care Center (Puskesmas area) of the Pulo Gadung District East Jakarta. Subjects received either a trivalent influenza vaccine or placebo at the start of the study, and a probiotic supplement (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011) or a placebo for 6 months. Subjects were randomly assigned into four intervention groups: influenza vaccine and probiotics (n = 141), influenza vaccine and placebo (n = 136), placebo and probiotics (n = 140), and both placebo (n = 137). The primary outcome was ILI incidence within 6 months. The secondary outcomes were seroprotection and seroconversion rates at 1, 4, and 6 months after administering the interventions. This study showed that the trivalent influenza vaccine increased seroprotection (RR 3.6 [95%CI 2.92-4.47]; p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0250234